Why Mounjaro can cause gallbladder issues — and what that means for you

You notice a dull ache under your right ribs a few weeks into treatment

That is one of the more common ways gallbladder trouble first makes itself known. Not crushing pain, just a nagging discomfort after eating, sometimes with bloating or queasiness. Many people assume it is ordinary indigestion from the stomach-slowing effect of tirzepatide. That assumption is understandable, and often it is just that. But gallbladder pain has a different character: it tends to sit under the right ribs or radiate toward the right shoulder blade, and it often follows a fatty meal. Keeping a note of where the pain sits, when it arrives and what you have eaten can help a clinician distinguish the two.

If you are wondering whether Mounjaro causes gallbladder problems, the connection sits inside a well-understood chain of events. Rapid weight loss (of the kind seen in clinical trials) causes the liver to secrete more cholesterol into bile, making it thicker and more likely to form crystals. At the same time, GLP-1 receptor activation slows gastric motility, and that slower movement appears to reduce how forcefully and frequently the gallbladder squeezes its bile into the digestive tract. When bile sits for longer, it becomes more concentrated. Over weeks and months that can produce sludge or, eventually, stones. The full Mounjaro side-effects overview places gallbladder events in the broader picture of what the clinical programme found.

One misconception worth setting aside gently: some people assume gallbladder problems with Mounjaro mean the drug is directly toxic to the organ. It is not. The gallbladder is a bystander, caught in the downstream effects of rapid weight change rather than targeted by tirzepatide itself. The same risk exists with any treatment or surgery that produces fast weight loss, Mounjaro is not uniquely harsh here.

How common are gallbladder issues on Mounjaro, and who is more likely to be affected?

In the SURMOUNT-1 trial, gallbladder-related adverse events occurred in a small but meaningful proportion of participants, with cholelithiasis (gallstones) being the most common finding. Rates were higher than in the placebo group, consistent with the weight-loss mechanism described above. The NHS medicines page for tirzepatide categorises gallbladder problems among side effects that affect a smaller subset of people but that need prompt attention when they do arise.

Certain factors increase the baseline risk. Women, people over 40, those who are or have recently been significantly above their target weight, and people with a personal or family history of gallstones all face a higher starting probability. Losing weight very quickly, regardless of the method, adds to that. None of this means people in these groups should avoid tirzepatide (for many, the cardiovascular and metabolic benefits outweigh the gallbladder risk considerably) but it is a conversation worth having with a prescriber before a pen is dispensed. The detailed guide to Mounjaro and the gallbladder covers the risk factors in more depth.

People who want to understand more fully how Mounjaro affects the gallbladder can find that those who have already had their gallbladder removed can still use the treatment; the organ's absence does not prevent treatment, though post-cholecystectomy digestive patterns may interact with the GI side effects of tirzepatide. That too is a prescriber-level conversation, not a reason to self-exclude.

When to get medical help (and what cannot wait

Most Mounjaro-related digestive discomfort) nausea, loose stools, reflux, is mild and settles as the body adjusts. Gallbladder pain is different in quality and needs a different response. Seek urgent medical assessment if you develop any of the following: severe or sharp pain in the upper right abdomen or centre of your chest that builds over 20–30 minutes; pain that spreads to your back or right shoulder; fever alongside abdominal pain; jaundice (yellowing of the skin or whites of the eyes); or vomiting that you cannot keep down. These signs can point to cholecystitis (gallbladder inflammation), a blocked bile duct, or (in rarer cases) pancreatitis, which the MHRA highlighted in a January 2026 Drug Safety Update on GLP-1 medicines. Pancreatitis typically presents as severe, persistent stomach pain that reaches through to the back; it is uncommon but serious.

Do not wait for your next scheduled review if the pain is severe or comes with fever and vomiting. Go to A&E or call 111. If you experience something less dramatic but recurrent (a dull ache after eating that keeps returning) flag it to your prescriber at the next opportunity rather than ignoring it. You can also report any suspected side effect through the MHRA Yellow Card scheme, which helps regulators track real-world patterns in medicines safety. It takes a few minutes and genuinely contributes to the post-market safety picture for tirzepatide, which still carries a Black Triangle (▼) status indicating it is under additional MHRA monitoring.

What you can do, and how a prescriber helps

There are practical steps that appear to reduce gallbladder risk during weight-loss treatment. Keeping weight loss steady rather than extremely rapid is probably the most significant. Eating regular meals (even smaller ones) rather than going long periods without food helps keep the gallbladder contracting at a reasonable rhythm. Avoiding very-high-fat meals in one sitting reduces the demand placed on the organ at any single moment. These are consistent with the lifestyle advice that accompanies Mounjaro treatment anyway, so they sit naturally alongside the prescription rather than adding a separate burden. For more on managing the risk proactively, the guide to avoiding gallbladder problems on Mounjaro goes into the practical detail.

At nume, our prescribers discuss your full medical history as part of the consultation, including any gallbladder history and relevant symptoms. Nothing about that process is a tick-box exercise. If there are features of your history that change the risk-benefit calculation, that conversation happens before treatment is approved. If you are already on tirzepatide and developing symptoms that concern you, our aftercare team is available seven days a week. You can also explore what an evidence-based, clinically supervised start to treatment looks like through a free consultation with our prescribers, who cover suitability and side effects as standard. The Mounjaro treatment page outlines what the full treatment pathway at nume involves.